<DOC>
	<DOCNO>NCT01519882</DOCNO>
	<brief_summary>This phase 4 study evaluate Polysomnography ( PSG ) subjective measure effect Rotigotine sleep efficiency , maintenance , insomnia , nocturnal akinesia night-time movement bed , patient advance Parkinson 's disease .</brief_summary>
	<brief_title>Sleep Efficiency Assessed Polysomnography ( PSG Sleep Lab Testing ) Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Advanced Parkinson 's disease ( ie , take Levodopa ( LDOPA ) ) Hoehn Yahr stage score 2 4 Subject sleepmaintenance insomnia Significant skin disease would make transdermal drug use inappropriate Subject receive therapy controlledrelease Levodopa ( LDOPA ) , entacapone StalevoÂ® within 28 day prior Baseline Visit receive therapy Tolcapone Atypical Parkinsonian syndromes Previous diagnosis Narcolepsy , Sleep Apnoea Syndrome , significant Rapid Eye Movement ( REM ) Sleep Behavior Disorder ( RBD ) , moderate severe Restless Legs Syndrome ( RLS ) Periodic Limb Movement Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
	<keyword>Polysomnography</keyword>
	<keyword>Sleep efficiency</keyword>
	<keyword>Advanced Idiopathic Parkinson 's Disease</keyword>
	<keyword>Sleep Disorder</keyword>
</DOC>